Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Prokidney Corp.
Headquarters: Winston-Salem, NC, United States of America
Website: http://www.prokidney.com/
Year Founded: 2015
Status: Public
Industry Sector: HealthTechnology
CEO: Bruce Culleton, MD, MBA
Number Of Employees: 163
Enterprise Value: $1,246,046,321
PE Ratio: -1.71
Exchange/Ticker 1: NASDAQ:PROK
Exchange/Ticker 2: N/A
Latest Market Cap: $121,915,104
BioCentury | Oct 16, 2024
Management Tracks
KdT promotes Grayeski, Malone as firm unveils new fund
Plus: Glaub, Enright become CEO, chair at CuraSen and updates from Volastra, Essential Pharma and Transpire
BioCentury | Jun 14, 2024
Finance
Public Equity Report: IPO action from QuantumPharm, Ascentage, Alumis, Telix
Plus: Fundraising by Avidity, Ultragenyx, ProKidney, Disc Medicine, Opthea and Replimmune
BioCentury | Mar 26, 2024
Management Tracks
Former BioMarin CEO Bienaimé named chair of Owkin
Plus: Dyne shares slip with CEO departing, and updates from Ardelyx and ProKidney
BioCentury | Jul 18, 2023
Management Tracks
Ballinger at the helm at Lyndra
Plus: Bryan Stuart to lead Atavistik and updates from EnteroBiotix, PTC, CureVac, CytomX, ProKidney and more
BioCentury | May 4, 2023
Management Tracks
Serrano named new director of FDA’s Europe office
Plus: Cochlovius becomes CEO at Eleva, and updates from Forbion, Vaccentis and Vera
BioCentury | Dec 21, 2022
Data Byte
Pace of biotech-SPAC mergers remains steady in 2H22
SPACs continue to be a viable IPO alternative, with at least 10 biotechs expecting to start trading in 1H23
BioCentury | Aug 13, 2022
Management Tracks
Schantz to oversee clinical trials at Bayer’s AskBio
Plus Liu to be CEO at Silexon and ProKidney adds Maraganore, Fox to board
BioCentury | Jul 21, 2022
Management Tracks
Versanis recruits Pruzanski as CEO, adds Maraganore, Duncan to board
Plus BMS’s new pricing SVP and updates from Forbion, Nuvalent and more
BioCentury | Jul 16, 2022
Finance
July 15 Quick Takes: 10X tumble
Plus DTC genetics co Nucleus raises $14M, and updates from SK biosciences, TH, Mosanna, ProKidney and more
Items per page:
1 - 9 of 9